David Schnell
Director @ Alvine Pharmaceuticals
Palo Alto, United States
David Schnell is a Managing Director of Prospect Venture Partners. David Schnell co-founded Prospect Venture Partners I with Alex Barkas, and Prospect Venture Partners II, and III with Barkas and Russell Hirsch. Prospect Ventures funds are dedicated life science funds with more than $1 billion under management. David Schnell has been activelyinvolved in the formation and growth of numerous successful biomedical and health care companies.He has lead investments and served on the Board of Directors of Gloucester Pharmaceuticals (NASDAQ: CELG acquired), Healtheon (NASDAQ: HLTH), Kythera Biopharmaceuticals, Lux Biosciences, Microcide Pharmaceuticals (NASDAQ: MCDE), Neurocrine Biosciences (NASDAQ: NBIX), NGM Biopharmaceuticals, Nora Therapeutics, Rinat Neuroscience (NYSE: PFE acquired), Senomyx (NASDAQ:SNMX), Trubion Pharmaceuticals (NASDAQ: TRBN), as well as several other privately held companies.David Schnell received an M.D. from Harvard Medical School, an M.A. in Health Services Research from Stanford University School of Medicine, and a B.S. in Biological Sciences from Stanford University.
- Total investments:
- 16
- Last investment:
- Lead investor:
- 38%
Last updated:
For AI agents: llms.txt
Industries David Schnell invests in
Stages David Schnell invests in
Countries David Schnell invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Biotechnology 6 (38%)
- Health Care 4 (25%)
- Medical 3 (19%)
- Pharmaceutical 3 (19%)
- Biopharma 2 (13%)
Stage
- Series B 6 (38%)
- Series A 3 (19%)
- Series D 3 (19%)
- Series C 2 (13%)
- Funding Round 1 (6%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
NGM Biopharmaceuticals
|
NGM Biopharmaceuticals is a privately-held drug discovery company committed to identifying transformational medicines that dramatically improve human health. Based on emerging human clinical and genetic observations, the company has devised several innovative experimental approaches to discover new therapies for the treatment of metabolic andcardiovascular diseases. The company's current focus is on the gastrointestinal endocrine system, with an aim to identify novel factors implicated in the pathogenesis of type 2 diabetes and the apparent resolution of this grievous disease in patients who have undergone gastric bypass surgery. | $57.5M / Series D / Mar 23, 2015 | |
|
NGM Biopharmaceuticals
|
NGM Biopharmaceuticals is a privately-held drug discovery company committed to identifying transformational medicines that dramatically improve human health. Based on emerging human clinical and genetic observations, the company has devised several innovative experimental approaches to discover new therapies for the treatment of metabolic andcardiovascular diseases. The company's current focus is on the gastrointestinal endocrine system, with an aim to identify novel factors implicated in the pathogenesis of type 2 diabetes and the apparent resolution of this grievous disease in patients who have undergone gastric bypass surgery. | $50M / Series C / Jul 18, 2013 | |
Satori Pharmaceuticals
|
Satori Pharmaceuticals is a neuroscience company focused on the discovery and development of disease-modifying therapies for Alzheimer's disease, Parkinson's disease and other neurodegenerative disorders. | $15M / Feb 23, 2012 | |
Kythera Biopharmaceuticals
|
KYTHERA Biopharmaceuticals, Inc., formerly known as AESTHERx, Inc., was founded in August 2005 and is a privately held biopharmaceutical company located north of Los Angeles in southern California.KYTHERA is focused on science and innovation in aesthetic medicine. This market is expanding rapidly driven by an aging population, increasingdiscretionary income, and an evolution of patient preference toward restorative and preventative care. The company uses the tools of biotechnology to develop prescription therapeutics for this emerging market. | $37.4M / Series D / Sep 19, 2011 | |
|
Satori Pharmaceuticals
|
Satori Pharmaceuticals is a neuroscience company focused on the discovery and development of disease-modifying therapies for Alzheimer's disease, Parkinson's disease and other neurodegenerative disorders. | $7M / Series B / Jan 05, 2011 | |
|
NGM Biopharmaceuticals
|
NGM Biopharmaceuticals is a privately-held drug discovery company committed to identifying transformational medicines that dramatically improve human health. Based on emerging human clinical and genetic observations, the company has devised several innovative experimental approaches to discover new therapies for the treatment of metabolic andcardiovascular diseases. The company's current focus is on the gastrointestinal endocrine system, with an aim to identify novel factors implicated in the pathogenesis of type 2 diabetes and the apparent resolution of this grievous disease in patients who have undergone gastric bypass surgery. | $55.4M / Series B / Mar 15, 2010 | |
|
NGM Biopharmaceuticals
|
NGM Biopharmaceuticals is a privately-held drug discovery company committed to identifying transformational medicines that dramatically improve human health. Based on emerging human clinical and genetic observations, the company has devised several innovative experimental approaches to discover new therapies for the treatment of metabolic andcardiovascular diseases. The company's current focus is on the gastrointestinal endocrine system, with an aim to identify novel factors implicated in the pathogenesis of type 2 diabetes and the apparent resolution of this grievous disease in patients who have undergone gastric bypass surgery. | $26.6M / Series A / Dec 22, 2009 | |
Lux Biosciences
|
Lux Biosciences, Inc., a biotechnology company, develops medications to treat ophthalmic diseases. Its products include LX201, a silicone matrix ocular implant that enables the release of cyclosporine A to the eye for one year; Luveniq, an oral form of calcineurin inhibitor voclosporin; LX212, a bioerodible polymer implant that containsvoclosporin; and LX214, a topical mixed nanomicellar formulation of voclosporin therapy for dry eyes. The company was founded in 2005 and is based in Jersey City, New Jersey. | $50M / Series B / Oct 01, 2009 | |
Gloucester Pharmaceuticals
|
Gloucester Pharmaceuticals is a biopharmaceutical company owned by hematological malignancies. The Company retains worldwide exclusive rights to romidepsin, an oncology candidate within a new class of anti-cancer agents known as histone deacetylase (HDAC) inhibitors. Preclinical studies suggest that romidepsin is a potent inhibitor of Class I, Class II and Class IV HDACs. | $29M / Series D / Aug 25, 2009 | |
|
Satori Pharmaceuticals
|
Satori Pharmaceuticals is a neuroscience company focused on the discovery and development of disease-modifying therapies for Alzheimer's disease, Parkinson's disease and other neurodegenerative disorders. | $22M / Series A / Jan 08, 2009 | |
| See all 16 investments → | |||
Co-Investors
About Alvine Pharmaceuticals
Alvine Pharmaceuticals, Inc. is a privately held biopharmaceutical company dedicated to developing and commercializing therapeutics for autoimmune/gastrointestinal diseases. Alvine's lead product candidate, ALV003, is a combination protease engineered to digest gluten. It is being developed to treat patients with celiac disease.
Alvine Pharmaceuticals Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Michale Powell
Director
|
|||
|
Bill Ringo
Director
|
|||
Chaitan S. Khosla
Scientific Founder
|
|||
|
David Schnell
Director
|
|||
|
James D. Watson
Chief Business Officer, Senior Vice President
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does David Schnell invest in?
David Schnell invests primarily in Biotechnology, Health Care and Medical startups, most often at Series B and Series A stage. Most of the 16 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact David Schnell?
For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did David Schnell last invest?
The most recent investment recorded for David Schnell closed in Mar 2015. Shizune tracks 16 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
